



PATENT
ATTORNEY DOCKET NO. 50111/002002

Certificate of Mailing: Date of Deposit: February 22, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Santa Zingariello
Printed name of person mailing correspondence

Santa Zingariello
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Neil R. Cashman et al.	Art Unit:	1648
Serial No.:	09/602,775	Examiner:	Ulrike Winkler
Filed:	June 23, 2000	Customer No.:	21559
Title:	PRION PROTEIN PEPTIDES AND USES THEREOF		

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Pursuant to 37 C.F.R. § 1.97(b)(4), this statement is being filed before the mailing of a first Office action after the filing of a Request for Continued Examination under 37


C.F.R. § 1.114. A check for \$180.00 in payment of the late submission fee set forth in 37

C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account
No. 03-2095.


Respectfully submitted,

Date: 22 February 2005



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 5

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.

50111/002002

Serial No.

09/602,775

Applicant

Neil R. Cashman et al.

Filing Date

June 23, 2000

Group

1648

IDS Filed

February 22, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,806,627	2/21/89	Wisniewski et al.			
	5,597,725	1/28/97	Suzuki			
	5,639,634	6/17/97	Suzuki			
	5,643,781	7/1/97	Suzuki			
	5,646,250	7/8/97	Suzuki			
	5,663,300	9/2/97	Suzuki			
	5,679,530	10/21/97	Brentani et al.			
	5,708,143	1/13/98	Suzuki			
	5,798,224	8/25/98	Suzuki			
	5,891,706	4/6/99	Suzuki			
	6,150,172	11/21/00	Schmerr et al.			
	6,261,790 B1	07/17/01	O'Rourke			
	6,372,214 & X6	4/16/02	Prusiner et al.			
	6,462,171	10/8/02	Soto-Jara et al.			


FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	SU 1529119 A1	12/15/89	Soviet Union			
	WO 87/06706	11/05/87	WIPO			
	WO 92/06220	4/16/92	WIPO			
	WO 92/08731	5/29/92	WIPO			
	WO 94/01116	1/20/94	WIPO			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



Sheet 2 of 5


INSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/002002
		Serial No.	09/602,775
		Applicant	Neil R. Cashman et al.
		Filing Date	June 23, 2000
		Group	1648
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		IDS Filed	February 22, 2005
(37 C.F.R. § 1.98(b))			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
	WO 96/32128	10/17/96	WIPO			
	WO 97/16728	5/9/97	WIPO			
	WO 97/43649	11/20/97	WIPO			
	WO 99/42829	08/26/99	WIPO			
	WO 00/78344 A1	12/28/00	WIPO			
	WO 01/00235	01/04/01	WIPO			
	WO 04/029072 A2	04/08/04	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Bacon and Anderson, "Multiple Sequence Alignment," <i>J. Mol. Biol.</i> 191:153-161 (1986).					
	Bennett et al., "3D Domain Swapping: A Mechanism for Oligomer Assembly," <i>Protein Science</i> 4:2455-2468 (1995).					
	Bolton and Bendheim, "A Modified Host Protein Model of Scrapie," <i>Ciba Found. Symp.</i> 135:164-181 (1988).					
	Bradley, "BSE Transmission Studies with Particular Reference to Blood," <i>Dev. Biol. Stand.</i> 99:35-40 (1999).					
	Brown et al., "Iatrogenic Creutzfeldt-Jakob Disease at the Millennium," <i>Neurology</i> 55:1075-1081 (2000).					
	Büeler et al., "Mice Devoid of PrP are Resistant to Scrapie," <i>Cell</i> 73:1339-1347 (1993).					
	Büeler et al., "Normal Development and Behaviour of Mice Lacking the Neuronal Cell-Surface PrP Protein," <i>Nature</i> 356:577-582 (1992).					
	Cashman, "A Prion Primer," <i>CMAJ</i> 157:1381-1385 (1997).					
	Cashman et al., "A Prion-Specific Immunological Epitope," <i>Society for Neuroscience Abstracts</i> 27:1743 (2001).					
	Cashman et al., "Cellular Isoform of the Scrapie Agent Protein Participates in Lymphocyte Activation," <i>Cell</i> 61:185-192 (1990).					
	Caughey et al., "Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glycosaminoglycan and Congo Red," <i>J. Virol</i> 68: 2135-2141 (1994).					
	Caughey, "Probing for Prions: Recognizing Misfolded PrP," <i>Nature Medicine</i> 9:819-820 (2003).					
	Chandler, "Encephalopathy in Mice Produced by Inoculation with Scrapie Brain Material," <i>Lancet</i> 6:1378-1379 (1961).					
	Collinge et al., "Prion Protein is Necessary for Normal Synaptic Function," <i>Nature</i> 370:295-297 (1994).					

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 (REVISED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/002002
		Serial No.	09/602,775
		Applicant	Neil R. Cashman et al.
		Filing Date	June 23, 2000
		Group	1648
		IDS Filed	February 22, 2005

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Collinge, "Variant Creutzfeldt-Jakob Disease," <i>Lancet</i> 354:317-323 (1999).
	Come et al., "A Kinetic Model for Amyloid Formation in the Prion Diseases: Importance of Seeding," <i>Proc. Natl. Acad. Sci. USA</i> 90: 5959-5963 (1993)
	Coulthart and Cashman, "Variant Creutzfeldt-Jakob Disease: A Summary of Current Scientific Knowledge in Relation to Public Health," <i>CMAJ</i> 165:51-58 (2001).
	Dayhoff et al., "A Model of Evolutionary Change in Proteins," <i>Atlas Protein Sequence and Structure</i> 5:345-352 (1978).
	Eklund et al., "Pathogenesis of Scrapie Virus Infection in the Mouse," <i>J. Infectious Disease</i> 117:15-22 (1967).
	Endo et al., "Diversity of Oligosaccharide Structures Linked to Asparagines of the Scrapie Prion Protein," <i>Biochem.</i> 28:8380-8388 (1989).
	Engelman et al., "Identifying Nonpolar Transbilayer Helices in Amino Acid Sequences of Membrane Proteins," <i>Annu. Rev. Biophys. Biophys. Chem.</i> 15:321-353 (1986).
	Field, "Slow Virus Infections of the Nervous System," <i>Brit. J. Exp. Path.</i> 8:129-239 (1969).
	Fisher, "Vaccine in Mice Offers Hope in Fight Against Alzheimer's," <i>The New York Times, National</i> , pg. A16, July 8, (1999).
	Gorochov et al., "Properties of a Disease Specific Prion Probe," <i>Nature Medicine</i> 10:11 (2004).
	Horiuchi et al., "Inhibition of Interactions and Interconversions of Prion Protein Isoforms by Peptide Fragments from the C-terminal Folded Domain," <i>J. Biol. Chem.</i> 276: 15489-15497 (2001).
	Houston et al., "Influence of Preformed α -helix and α -helix Induction on the Activity of Cationic Antimicrobial Peptides," <i>J. Peptide Res.</i> 52:81-88 (1998).
	Houston et al., "Transmission of BSE by Blood Transfusion in Sheep," <i>Lancet</i> 356: 999-1000 (2000).
	Kyte and Doolittle, "A Simple Method for Displaying the Hydropathic Character of a Protein," <i>J. Mol. Biol.</i> 157:105-132 (1982).
	Li et al., "The Expression and Potential Function of Cellular Prion Protein in Human Lymphocytes," <i>Cell. Immunol.</i> 207:49-58 (2001).
	McKinley et al., "A Protease-Resistant Protein Is a Structural Component of the Scrapie Prion," <i>Cell</i> 35:57-62 (1983).
	Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2154 (1963).
	Moore et al., "Ataxia in Prion Protein (PrP)-Deficient Mice is Associated with Upregulation of the Novel PrP-Like Protein Doppel," <i>J. Mol. Biol.</i> 292:797-817 (1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/002002
		Serial No.	09/602,775
		Applicant	Neil R. Cashman et al.
		Filing Date	June 23, 2000
		Group	1648
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		IDS Filed	February 22, 2005
		(37 C.F.R. § 1.98(b))	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Morel et al., "Selective and Efficient Immunoprecipitation of the Disease-Associated Form of the Prion Protein can be Mediated by Nonspecific Interactions between Monoclonal Antibodies and Scrapie-Associated Fibrils," <i>J. Biol Chem.</i> 279: 30143-30149 (2004).
	Morignat et al., "Targeted Surveillance to Assess the Prevalence of BSE in High-Risk Populations in Western France and the Associated Risk Factors," <i>Veterinary Record</i> 151:73-77 (2002).
	Oesch et al., "Application of Prionics Western Blotting Procedure to Screen for BSE in Cattle Regularly Slaughtered at Swiss Abattoirs," <i>Arch. Virol. Supp.</i> 16:189-195 (2000).
	Oesch et al., "A Cellular Gene Encodes Scrapie PrP 27-30 Protein," <i>Cell</i> 40:735-746 (1985).
	O'Rourke et al., "Preclinical Detection of PrP ^{Sc} in Nictitating Membrane Lymphoid Tissue of Sheep," <i>Veterinary Record</i> 142:489-491 (1998).
	Paramithiotis et al., "Properties of a Disease Specific Prion Probe, Reply," <i>Nature Medicine</i> 10:11-12 (2004).
	Pattison, "The Emergence of Bovine Spongiform Encephalopathy and Related Diseases," <i>Emerg Infect Dis</i> 4:390-394 (1998).
	Prusiner, "Molecular Biology of Prion Diseases," <i>Science</i> 252:1515-1522 (1991).
	Prusiner et al., "Ablation of the Prion Protein (PrP) Gene in Mice Prevents Scrapie and Facilitates Production of Anti-PrP Antibodies," <i>Proc. Natl. Acad. Sci., USA</i> 90:10608-10612 (1993).
	Prusiner et al., "Further Purification and Characterization of Scrapie Prions," <i>Biochem.</i> 21:6942-6950 (1982).
	Ricketts et al., "Is Creutzfeldt-Jakob Disease Transmitted in Blood," <i>Emerg Infect Dis</i> 3:155-163 (1997).
	Schaller et al., "Validation of a Western Immunoblotting Procedure for Bovine PrP ^{Sc} Detection and Its Use as a Rapid Surveillance Method for the Diagnosis of Bovine Spongiform Encephalopathy (BSE)," <i>Acta Neuropathol.</i> 98: 437-443 (1999).
	Shyng et al., "Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrP _C , in Cultured Cells," <i>Journal of Biological Chemistry</i> 270:30221-30229 (1995).
	St. George-Hyslop et al., "Antibody Clears Senile Plaques," <i>Nature</i> 400:116-117 (1999).
	Tam, "Recent Advances in Multiple Antigen Peptides," <i>J. Immunol. Methods</i> 196:17-32 (1996).
	Tam, "Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-Density Multiple Antigenic Peptide System," <i>Proc Natl. Acad. Sci., USA</i> 85: 5409-5413 (1988).
	Tam and Zavala, "Multiple Antigen Peptide," <i>J. Immunol. Methods</i> 124:53-61 (1989).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

